CRBN
ENSG00000113851
Target class
Unclassified protein
Chromosome
3
Approved drugs
4
Clinical candidates (approved and in development)
5
- Approved drugs
- 4
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Other names
- MRT2
- Target name
- CRBN
- Gene name
- Cereblon
- Gene symbol
- CRBN
- Previous gene symbols
- MRT2A
- Protein name
- Protein cereblon
- Gene biotype
- Protein coding
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 40.85
- Tissue specificity (Gini)
- 0.204
- Tissue specificity (tau)
- 0.416
- KEGG gene identifiers
- hsa:51185
- Reactome pathways
- R-HSA-9679191
- Protein interaction confidence
- 0.883717
- Protein interaction partners
- 60
- End position
- 3179727
- Start position
- 3144628
- Chromosome
- 3
- Strand
- Reverse
- Cytoplasm . Nucleus . Membrane
- Peripheral membrane protein .
Publication evidence
- PubMed 20223979
- Tissue specificity (tau)
- 0.415944
- Expression inequality (Gini)
- 0.203697
Expression in transcripts per million
- Nerve - Tibial
- 40.85
- Testis
- 39.61
- Artery - Tibial
- 39
- Ovary
- 38.12
- Brain - Cerebellar Hemisphere
- 37.42
Expression in transcripts per million
- Nerve - Tibial40.85
- Testis39.61
- Artery - Tibial39
- Ovary38.12
- Brain - Cerebellar Hemisphere37.42
- Uterus36.63
- Cervix - Ectocervix36.5
- Brain - Spinal cord (cervical c-1)34.38
- Cervix - Endocervix33.82
- Adipose - Subcutaneous33.24
- Fallopian Tube32.75
- Bladder30.8
- Thyroid30.56
- Brain - Cerebellum30.52
- Artery - Coronary30.33
- Colon - Sigmoid30.14
- Breast - Mammary Tissue30.04
- Brain - Frontal Cortex (BA9)28.86
- Artery - Aorta28.52
- Esophagus - Gastroesophageal Junction28.39
- Esophagus - Muscularis27.64
- Lung27.63
- Spleen27.22
- Vagina25.26
- Prostate24.9
And 29 more, listed on the interactive page.
- GO:0016567
- GO:0030177
- GO:0043161
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0031464
Molecular functions
- GO:0005515
Related records
Trials (1,854)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
Drugs (5)
- Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide hydrochloride monohydrate CRL4(CRBN) E3 ubiquitin ligase modulator
- Pomalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor